zykadia
Moffitt scientists discover new applications for Novartis’s Zykadia
October 11, 2017Research and Development Cancer, Moffitt, NSCLC, ceritinib, lung cancer, zykadia
Through the use of molecular screening, functional proteomics and computer-based modelling, researchers from the Moffitt Cancer Center have been working …
Novartis’ Zykadia scores priority review and breakthrough designation from FDA
February 23, 2017Sales and Marketing Novartis, zykadia
Novartis’ lung cancer treatment Zykadia (ceritinib) has been awarded both priority review and breakthrough therapy designation by the US Food …
Novartis’ Zykadia more effective than chemo, new study shows
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia
Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …
Novartis’ Zykadia smashes Phase III target for lung cancer
September 23, 2016Medical Communications, Research and Development Novartis, lung cancer, zykadia
Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating …
Cancer and MS drugs approved in Scotland
December 9, 2015Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia
The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
Novartis in major oncology drive
March 30, 2015Research and Development, Sales and Marketing Cancer, FDA, MHRA, Novartis, aduro, ceritinib, eams, early access, zykadia
Novartis says it is ‘stepping up its efforts’ in cancer by launching major initiatives to discover new treatments to combat …
Three drugs put forward for EMA authorisation
March 2, 2015Research and Development, Sales and Marketing Amgen, EMA, FDA, Novartis, Otsuka, jinarc, ristempa, zykadia
Novartis’ lung cancer drug Zykadia has been recommended for EU approval in patients previously treated with Pfizer’s Xalkori – the …
FDA approves Zykadia for late-stage lung cancer
April 30, 2014Research and Development, Sales and Marketing Cancer, FDA, Novartis, lung, zykadia
Novartis’ ‘breakthrough’ drug Zykadia has been approved by the FDA to treat lung cancer patients with a particular genetic mutation. …
